330 related articles for article (PubMed ID: 26683130)
1. PET Imaging in Huntington's Disease.
Roussakis AA; Piccini P
J Huntingtons Dis; 2015; 4(4):287-96. PubMed ID: 26683130
[TBL] [Abstract][Full Text] [Related]
2. Neuroinflammation in Huntington's Disease: New Insights with
Lois C; González I; Izquierdo-García D; Zürcher NR; Wilkens P; Loggia ML; Hooker JM; Rosas HD
ACS Chem Neurosci; 2018 Nov; 9(11):2563-2571. PubMed ID: 29719953
[TBL] [Abstract][Full Text] [Related]
3. Current status of PET imaging in Huntington's disease.
Pagano G; Niccolini F; Politis M
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1171-82. PubMed ID: 26899245
[TBL] [Abstract][Full Text] [Related]
4. Molecular Imaging in Huntington's Disease.
Wilson H; Politis M
Int Rev Neurobiol; 2018; 142():289-333. PubMed ID: 30409256
[TBL] [Abstract][Full Text] [Related]
5. Huntington's Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers.
Cybulska K; Perk L; Booij J; Laverman P; Rijpkema M
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979301
[TBL] [Abstract][Full Text] [Related]
6. Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.
Sampedro F; Martínez-Horta S; Perez-Perez J; Horta-Barba A; Lopez-Mora DA; Camacho V; Fernández-León A; Gomez-Anson B; Carrió I; Kulisevsky J
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1111-1116. PubMed ID: 30627816
[TBL] [Abstract][Full Text] [Related]
7. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
[TBL] [Abstract][Full Text] [Related]
8. Molecular Imaging Markers to Track Huntington's Disease Pathology.
Wilson H; De Micco R; Niccolini F; Politis M
Front Neurol; 2017; 8():11. PubMed ID: 28194132
[TBL] [Abstract][Full Text] [Related]
9. TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31.
Simmons DA; James ML; Belichenko NP; Semaan S; Condon C; Kuan J; Shuhendler AJ; Miao Z; Chin FT; Longo FM
Hum Mol Genet; 2018 Aug; 27(16):2893-2912. PubMed ID: 29860333
[TBL] [Abstract][Full Text] [Related]
10. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.
Russell DS; Jennings DL; Barret O; Tamagnan GD; Carroll VM; Caillé F; Alagille D; Morley TJ; Papin C; Seibyl JP; Marek KL
Neurology; 2016 Feb; 86(8):748-54. PubMed ID: 26802091
[TBL] [Abstract][Full Text] [Related]
11. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers.
Politis M; Lahiri N; Niccolini F; Su P; Wu K; Giannetti P; Scahill RI; Turkheimer FE; Tabrizi SJ; Piccini P
Neurobiol Dis; 2015 Nov; 83():115-21. PubMed ID: 26297319
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease.
Delva A; Van Laere K; Vandenberghe W
Mov Disord; 2023 Aug; 38(8):1515-1526. PubMed ID: 37382295
[TBL] [Abstract][Full Text] [Related]
13. Microglial activation in presymptomatic Huntington's disease gene carriers.
Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P
Brain; 2007 Jul; 130(Pt 7):1759-66. PubMed ID: 17400599
[TBL] [Abstract][Full Text] [Related]
14. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
[TBL] [Abstract][Full Text] [Related]
15. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
Feigin A; Leenders KL; Moeller JR; Missimer J; Kuenig G; Spetsieris P; Antonini A; Eidelberg D
J Nucl Med; 2001 Nov; 42(11):1591-5. PubMed ID: 11696626
[TBL] [Abstract][Full Text] [Related]
16. Metabolic network as a progression biomarker of premanifest Huntington's disease.
Tang CC; Feigin A; Ma Y; Habeck C; Paulsen JS; Leenders KL; Teune LK; van Oostrom JC; Guttman M; Dhawan V; Eidelberg D
J Clin Invest; 2013 Sep; 123(9):4076-88. PubMed ID: 23985564
[TBL] [Abstract][Full Text] [Related]
17. FDG μPET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease – A 15 Months Follow-up Study.
Reilmann R; Lippross V; Hölzner E; Gigengack F; Bohlen S; Kugel H; Deppe M; Osada N; Lücke M; Riess O; Nguyen HP; Von Hörsten S; Schäfers K; Schäfers M; Jacobs AH; Hermann S
J Huntingtons Dis; 2015; 4(1):37-47. PubMed ID: 26333256
[TBL] [Abstract][Full Text] [Related]
18. Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies.
Niccolini F; Pagano G; Fusar-Poli P; Wood A; Mrzljak L; Sampaio C; Politis M
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):185-196. PubMed ID: 28889093
[TBL] [Abstract][Full Text] [Related]
19. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.
Ciarmiello A; Cannella M; Lastoria S; Simonelli M; Frati L; Rubinsztein DC; Squitieri F
J Nucl Med; 2006 Feb; 47(2):215-22. PubMed ID: 16455626
[TBL] [Abstract][Full Text] [Related]
20. Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers.
Wilson H; Niccolini F; Haider S; Marques TR; Pagano G; Coello C; Natesan S; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
J Neurol Sci; 2016 Sep; 368():243-8. PubMed ID: 27538642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
